 BEVERLY HILLS, Calif., March 17, 2021 PRNewswire -- GT Biopharma, Inc. NASDAQ: GTBP a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Companys proprietary NK cell engager TriKETM protein biologic technology platform is pleased to announce updated interim Phase III clinical trial results for the Companys lead therapeutic candidate, GTB-3550, being evaluated for the treatment of high-risk myelodysplastic syndromes MDS and refractoryrelapsed acute myeloid leukemia AML. 